You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Moodys
McKinsey
Boehringer Ingelheim
Colorcon

Last Updated: March 29, 2020

DrugPatentWatch Database Preview

Par Pharm Inc Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for PAR PHARM INC, and what generic alternatives to PAR PHARM INC drugs are available?

PAR PHARM INC has forty-one approved drugs.

There is one US patent protecting PAR PHARM INC drugs. There are nine tentative approvals on PAR PHARM INC drugs.

There are nine patent family members on PAR PHARM INC drugs in eight countries and forty-nine supplementary protection certificates in twelve countries.

Summary for Par Pharm Inc
International Patents:9
US Patents:1
Tradenames:37
Ingredients:37
NDAs:41

Drugs and US Patents for Par Pharm Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Pharm Inc DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 206159-004 May 31, 2019 AB RX No No   Start Trial   Start Trial
Par Pharm Inc TIZANIDINE HYDROCHLORIDE tizanidine hydrochloride CAPSULE;ORAL 207199-003 Mar 14, 2017 AB RX No No   Start Trial   Start Trial
Par Pharm Inc MORPHINE SULFATE morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 200812-003 Nov 10, 2011 AB RX No No   Start Trial   Start Trial
Par Pharm Inc ITRACONAZOLE itraconazole CAPSULE;ORAL 205724-001 Dec 13, 2016 AB RX No No   Start Trial   Start Trial
Par Pharm Inc DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 206159-001 May 31, 2019 AB RX No No   Start Trial   Start Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-001 Sep 26, 1996 AB RX Yes Yes   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Par Pharm Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-001 Sep 26, 1996 5,583,152   Start Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-003 Sep 17, 1999 4,859,692   Start Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-001 Sep 26, 1996 5,319,097   Start Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-001 Sep 26, 1996 5,612,367   Start Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-003 Sep 17, 1999 5,612,367   Start Trial
Par Pharm Inc ACCOLATE zafirlukast TABLET;ORAL 020547-001 Sep 26, 1996 5,294,636   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for PAR PHARM INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 10 mg and 20 mg ➤ Subscribe 2008-02-29

Supplementary Protection Certificates for Par Pharm Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0503785 C300486 Netherlands   Start Trial PRODUCT NAME: COMBINATIE VAN OLMESARTANMEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, AMLODIPINEBESYLAAT AND HYDROCHLOORTHIAZIDE; NATL REGISTRATION NO/DATE: RVG 106667, RVG 106671-74, RVG 106682-86 20101221; FIRST REGISTRATION: DE 79810.00.00-79814.00.00 20101216
0481754 SPC/GB06/032 United Kingdom   Start Trial PRODUCT NAME: ENTECAVIR-(2-AMINO-1,9-DIHYDRO-9-((1S,3R,4S)-4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENE CYCLOPENTYL)-6H-PURIN-6-ONE AND HYDRATES THEREOF, PARTICULARLY THE MONOHYDRATE; REGISTERED: UK EU/1/06/343/001 20060626; UK EU/1/06/343/002 20060626; UK EU/1/06/343/003 20060626; UK EU/1/06/343/004 20060626; UK EU/1/06/343/005 20060626
1915993 C300625 Netherlands   Start Trial PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
2236132 CA 2015 00004 Denmark   Start Trial PRODUCT NAME: ZOLPIDEM OG FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER ZOLPIDEMTARTRAT; NAT. REG. NO/DATE: 47607 OG 47608 20120719; FIRST REG. NO/DATE: (B BE424286 OG BE424295 20120718
0443983 2007C/043 Belgium   Start Trial PRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222
1129088 2014/008 Ireland   Start Trial PRODUCT NAME: DEXLANSOPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: PA1864/001/001-002;PA1864/002/001-002 20131125; FIRST REGISTRATION NO/DATE: 47911 47912 47913 47914 20130919
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Colorcon
Baxter
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.